Rani Therapeutics Holdings, Inc. (RANI): Price and Financial Metrics


Rani Therapeutics Holdings, Inc. (RANI): $11.32

0.55 (+5.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RANI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RANI Stock Price Chart Interactive Chart >

Price chart for RANI

RANI Price/Volume Stats

Current price $11.32 52-week high $36.27
Prev. close $10.77 52-week low $9.24
Day low $10.68 Volume 18,700
Day high $12.00 Avg. volume 41,049
50-day MA $12.45 Dividend yield N/A
200-day MA $17.99 Market Cap 556.49M

Rani Therapeutics Holdings, Inc. (RANI) Company Bio


Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.


RANI Latest News Stream


Event/Time News Detail
Loading, please wait...

RANI Latest Social Stream


Loading social stream, please wait...

View Full RANI Social Stream

Latest RANI News From Around the Web

Below are the latest news stories about Rani Therapeutics Holdings Inc that investors may wish to consider to help them evaluate RANI as an investment opportunity.

Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results

- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development or partnership - - Company announces preliminary consolidated financial results for the fourth quarter and year ended December 31, 2021 - SAN JOSE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Na

Yahoo | February 23, 2022

MNTS, KOSS and HTOO among mid-day movers

Gainers: Weidai (WEI) +79%.Rani Therapeutics Holdings (RANI) +33%.Stride LRN +29%.Exela Technologies XELA +26%.Huadi International (HUDI) +21%.Koss (KOSS) +20%.Sierra (SRRA)

Seeking Alpha | January 26, 2022

5 Biotech Stocks That Are Bucking the Selloff

Biotech investors still like BioCryst, Protagonist, Prometheus Biosciences, Rani, and Emergent BioSolutions. All sported recent double-digit gains despite the sector slump.

Yahoo | January 19, 2022

Rani Therapeutics Appoints Lisa Rometty to Board of Directors

SAN JOSE, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the appointment of Lisa Rometty to its Board of Directors. Ms. Rometty brings significant global commercial leadership experience across a spectrum of start-ups to mature businesses in medical device, technology and pharmaceuticals. “In our effort to pioneer the fiel

Yahoo | January 7, 2022

Reviewing Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX)

Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Rani Therapeutics and Soligenix, […]

Dakota Financial News | December 24, 2021

Read More 'RANI' Stories Here

RANI Price Returns

1-mo 8.43%
3-mo -19.26%
6-mo -63.19%
1-year N/A
3-year N/A
5-year N/A
YTD -30.76%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9845 seconds.